📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
News
Sygnature Discovery and Viramatix Forge Strategic Alliance for Advancing Anti-Viral Drug Discovery
Sygnature Discovery Limited, the UK’s largest independent provider of integrated drug discovery resources and expertise,…
News
Sygnature further enhances capabilities and services within the translational sciences
Sygnature Discovery has released a biology publication focusing on our collaboration with Corcept Therapeutics. This…
News
Sygnature Discovery, Mironid®, and Peak Proteins Join Forces to Tackle Incurable Kidney Disease, ADPKD
Sygnature Discovery, Mironid® Limited, a leader in cell signalling-directed drug discovery and…
News
Sygnature has made the annual Sunday Times Lloyds SME Export Track 100 listing for the 3rd consecutive year due to the company’s increasing international client base
The Sunday Times Lloyds SME Export Track 100 ranks Britain’s 100 small and medium-sized (SME)…
News
Keapstone Therapeutics and Sygnature Discovery collaborate to discover new therapies for Parkinson’s and Motor Neuron Disease
Keapstone Therapeutics, a new biotech company formed by the University…
Journal Papers
Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus
Euan A F Fordyce, Daniel W Brookes, Claire Lise-Ciana, Matthew S Coates, S Fraser Hunt, Kazuhiro Ito, John King-Underwood, Stuart T Onions, Guillaume…
News
TopiVert and Sygnature Discovery: A Dual Triumph as Two Drug Candidates Commence Clinical Trials
One of Sygnature Discovery’s long-term clients, TopiVert Pharma, has recently initiated clinical trials with…
News
Sygnature Discovery ranked in FT1000: The Financial Times list of Europe’s 1,000 fastest-growing companies
Sygnature Discovery has been ranked 906th in the Financial Times FT1000 The FT1000 lists the 1,000…
News
Unveiling the Magnificent ‘Discovery Building’: Sygnature Discovery’s £30 Million State-of-the-Art Headquarters
Dr Jonathan Williams, COO, has given the “Nottingham Post” a tour of the…
News
Sygnature Discovery Honoured with Queen’s Award for Enterprise!
Sygnature Discovery has today been recognised with one of the UK’s most prestigious business awards…
News
Sygnature Discovery récompensée par le Queen’s Award for Enterprise !
La société Sygnature Discovery a été récompensée aujourd’hui par l’un des prix d’entreprise les plus…
News
Sygnature Discovery Expands Biophysics Capability with the Introduction of Biacore 8K SPR System
Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise,…
News
Sygnature Discovery Named Among London Stock Exchange Group’s “1000 Companies Inspiring Britain”
The report is a celebration of the UK’s fastest-growing and most dynamic small and medium…
News
Midlands Engine Chairman, Sir John Peace, Inaugurates Sygnature’s New HQ – The Discovery Building
Sir John Peace has officially opened Sygnature Discovery’s new HQ, the purpose-built Discovery Building…
News
Sygnature Discovery Receives Prestigious Queen’s Award for Enterprise 2017 During VIP Ceremony
Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has…
News
Sygnature Discovery reçoit le prestigieux Queen’s Award for Enterprise 2017 lors d’une cérémonie VIP.
Sygnature Discovery, le plus grand fournisseur indépendant britannique de ressources et d’expertise intégrées en matière…
News
Sygnature Discovery Earns Finalist Spot in OBN Awards 2017 – Best CRO Category
Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise,…
News
Sygnature Discovery Clinches Top Honors as Best Contract Research Organisation at OBN Awards 2017
Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise,…
News
Phoenix Equity Partners announces investment in Sygnature Discovery
Phoenix Equity Partners (“Phoenix”), a leading UK middle-market private equity firm, today announces an…
News
Phoenix Equity Partners annonce un investissement dans Sygnature Discovery
Phoenix Equity Partners (« Phoenix »), société de capital-investissement britannique de premier plan…
Journal Papers
Thermal Shift as an Entropy-Driven Effect
Martin Redhead, Rupert Satchell, Ciara McCarthy, Scott Pollack, John Unitt Abstract Thermal shift assays (TSAs)…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch